Reproxalap Uses, Dosage, Side Effects and more
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
| Trade Name | Reproxalap |
| Generic | Reproxalap |
| Reproxalap Other Names | ADX 102, ADX102, ALD-102, NS-2, Reproxalap |
| Type | |
| Formula | C12H13ClN2O |
| Weight | Average: 236.7 Monoisotopic: 236.0716407 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Reproxalap works
Reproxalap inhibits Reactive Aldehyde Species (RASP) and is being investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome.
